رجوع
45
نطاق اليوم
KWD 68.03
KWD 69.18
نطاق 52 أسبوعًا
KWD 67.56
KWD 109.50
حجم التداول
9,654,607
متوسط 50 يوم / 200 يوم
KWD 80.41
/
KWD 95.75
الإغلاق السابق
KWD 69.54
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (627 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 35.0 | 0.3 |
| P/B | 4.2 | 2.9 |
| ROE % | 12.6 | 3.7 |
| Net Margin % | 14.4 | 3.8 |
| Rev Growth 5Y % | 14.0 | 10.0 |
| D/E | 0.5 | 0.2 |
السعر المستهدف للمحللين
Hold
KWD 108.350
+59.0%
Low: KWD 94.000
High: KWD 130.000
مكرر الربحية المستقبلي
20.1
ربحية السهم المستقبلية
KWD 3.469
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
22 B
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2030 |
KWD 5.607
KWD 5.523 – KWD 5.766
|
33 B | 2 |
| FY2029 |
KWD 4.980
KWD 4.905 – KWD 5.121
|
30 B | 2 |
| FY2028 |
KWD 4.441
KWD 4.010 – KWD 5.087
|
27 B | 4 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 |
Morano Susan E
Director
|
grant | 24 | — | — |
| Mar 2, 2026 |
Pegus Cheryl
Director
|
grant | 24 | — | — |
| Mar 1, 2026 |
Woodworth Emily
SVP, Global Controller and CAO
|
other | 2,048 | — | — |
| Nov 28, 2025 |
O'Sullivan Miriam
SVP, Chief HR Officer
|
other | 260 | — | — |
| Nov 14, 2025 |
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
|
other | 9,610 | — | — |
| Nov 12, 2025 |
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
|
other | 690 | — | — |
| Aug 1, 2025 |
LUDWIG EDWARD J
Director
|
other | 500 | — | — |
| Jul 29, 2025 |
FUJIMORI YOSHIAKI
Director
|
sell | 2,901 | KWD 106.990 | KWD 310,378 |
| Jul 1, 2025 |
Monson Jonathan
EVP and CFO
|
grant | 30,523 | — | — |
| May 29, 2025 |
LUDWIG EDWARD J
Director
|
sell | 4,000 | KWD 104.592 | KWD 418,368 |
| May 21, 2025 |
Brown Vance R
SVP, GC and Corp. Secretary
|
sell | 4,826 | KWD 106.420 | KWD 513,583 |
| May 8, 2025 |
Habiger David C
Director
|
grant | 2,081 | — | — |
| May 8, 2025 |
WICHMANN DAVID S
Director
|
grant | 2,081 | — | — |
| May 8, 2025 |
Mega Jessica L
Director
|
grant | 2,081 | — | — |
| May 8, 2025 |
Zane Ellen M
Director
|
grant | 2,081 | — | — |
| May 8, 2025 |
LUDWIG EDWARD J
Director
|
grant | 2,081 | — | — |
| May 5, 2025 |
Sorenson John Bradley
EVP, Global Operations
|
sell | 4,572 | KWD 104.540 | KWD 477,957 |
| May 2, 2025 |
Sorenson John Bradley
EVP, Global Operations
|
other | 10,326 | — | — |
| May 2, 2025 |
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
|
other | 5,221 | — | — |
| Apr 21, 2025 |
Brown Vance R
SVP, GC and Corp. Secretary
|
sell | 4,826 | KWD 95.090 | KWD 458,904 |
النقاط الرئيسية
Revenue grew 13.99% annually over 5 years — strong growth
Earnings grew 55.66% over the past year
ROE of 12.55% — decent returns on equity
Generating 3.66B in free cash flow
P/E of 35.04 — premium valuation
PEG of 0.88 suggests growth is underpriced
النمو
Revenue Growth (5Y)
13.99%
Revenue (1Y)19.87%
Earnings (1Y)55.66%
FCF Growth (3Y)46.56%
الجودة
Return on Equity
12.55%
ROIC8.13%
Net Margin14.38%
Op. Margin19.78%
الأمان
Debt / Equity
0.51
Current Ratio1.62
Interest Coverage11.38
التقييم
P/E Ratio
35.04
P/B Ratio4.17
EV/EBITDA28.08
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 19.87% | Revenue Growth (3Y) | 18.73% |
| Earnings Growth (1Y) | 55.66% | Earnings Growth (3Y) | 34.60% |
| Revenue Growth (5Y) | 13.99% | Earnings Growth (5Y) | 29.07% |
| Profitability | |||
| Revenue (TTM) | 20.07B | Net Income (TTM) | 2.89B |
| ROE | 12.55% | ROA | 6.61% |
| Gross Margin | 69.01% | Operating Margin | 19.78% |
| Net Margin | 14.38% | Free Cash Flow (TTM) | 3.66B |
| ROIC | 8.13% | FCF Growth (3Y) | 46.56% |
| Safety | |||
| Debt / Equity | 0.51 | Current Ratio | 1.62 |
| Interest Coverage | 11.38 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 35.04 | P/B Ratio | 4.17 |
| P/S Ratio | 5.04 | PEG Ratio | 0.88 |
| EV/EBITDA | 28.08 | Dividend Yield | 0.00% |
| Market Cap | 101.13B | Enterprise Value | 111.50B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 20.07B | 16.75B | 14.24B | 12.68B | 11.89B |
| Net Income | 2.89B | 1.85B | 1.59B | 698.00M | 1.04B |
| EPS (Diluted) | 1.94 | 1.25 | 1.07 | 0.45 | 0.69 |
| Gross Profit | 13.85B | 10.27B | 8.83B | 7.71B | 7.46B |
| Operating Income | 3.97B | 2.64B | 2.18B | 1.82B | 1.92B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 43.67B | 39.40B | 35.14B | 32.47B | 32.23B |
| Total Liabilities | 19.20B | 17.39B | 15.61B | 14.90B | 15.61B |
| Shareholders' Equity | 24.23B | 21.77B | 19.28B | 17.57B | 16.62B |
| Total Debt | 12.42B | 11.15B | 9.49B | 9.28B | 9.45B |
| Cash & Equivalents | 2.05B | 414.00M | 865.00M | 928.00M | 1.93B |
| Current Assets | 8.79B | 6.92B | 6.51B | 5.76B | 6.32B |
| Current Liabilities | 5.44B | 6.40B | 4.93B | 3.80B | 4.27B |
درجات الاستراتيجيات
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#528 of 1052
النشاط الأخير
دخل
Cash Flow Compounder
Mar 24, 2026